Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy.

[1]  G. Filippatos,et al.  Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. , 2014, International journal of cardiology.

[2]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[3]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  V. Hasselblad,et al.  Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). , 2013, Journal of the American College of Cardiology.

[6]  K. Anstrom,et al.  Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial , 2013, Circulation. Heart failure.

[7]  F. Verbrugge,et al.  Abdominal contributions to cardiorenal dysfunction in congestive heart failure. , 2013, Journal of the American College of Cardiology.

[8]  G. Felker,et al.  Cardiohepatic interactions in heart failure: an overview and clinical implications. , 2013, Journal of the American College of Cardiology.

[9]  K. Swedberg,et al.  Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. , 2013, Journal of cardiac failure.

[10]  T. Koelling,et al.  Baseline Albumin Is Associated with Worsening Renal Function in Patients with Acute Decompensated Heart Failure Receiving Continuous Infusion Loop Diuretics , 2013, Pharmacotherapy.

[11]  M. Dorsch,et al.  The Effect of Continuous Infusion Loop Diuretics in Patients With Acute Decompensated Heart Failure With Hypoalbuminemia , 2013, Journal of cardiovascular pharmacology and therapeutics.

[12]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[13]  R. Starling,et al.  Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. , 2012, Journal of the American College of Cardiology.

[14]  C. Ronco,et al.  Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. , 2012, Journal of the American College of Cardiology.

[15]  G. Felker,et al.  Diuretics and ultrafiltration in acute decompensated heart failure. , 2012, Journal of the American College of Cardiology.

[16]  C. O'connor,et al.  Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. , 2012, Journal of cardiac failure.

[17]  C. Orlandi,et al.  A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. , 2011, Journal of cardiac failure.

[18]  M. Hori,et al.  Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study , 2011, Cardiovascular Drugs and Therapy.

[19]  Pierre Ambrosi,et al.  Human serum albumin in the clinical syndrome of heart failure. , 2011, Journal of cardiac failure.

[20]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[21]  Dirk Westermann,et al.  Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. , 2010, Journal of cardiac failure.

[22]  Adrian F. Hernandez,et al.  Combination of loop diuretics with thiazide-type diuretics in heart failure. , 2010, Journal of the American College of Cardiology.

[23]  Mhs G. Michael Felker.  Diuretic Management in Heart Failure , 2010 .

[24]  S. Gottlieb,et al.  Cardiorenal Syndrome: New Perspectives , 2010, Circulation.

[25]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[26]  Lawrence J. Appel,et al.  State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. , 2009, Circulation.

[27]  R. Schrier,et al.  Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? , 2009, Circulation. Heart failure.

[28]  Gary S Francis,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[29]  C. O'connor,et al.  Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil? , 2009, Circulation. Heart failure.

[30]  Rinaldo Bellomo,et al.  Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.

[31]  R. Starling,et al.  Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. , 2008, Journal of cardiac failure.

[32]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[33]  R. Califf,et al.  Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) , 2008, Circulation. Heart failure.

[34]  V. Hasselblad,et al.  Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.

[35]  R. Starling,et al.  Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? , 2008, Journal of the American College of Cardiology.

[36]  U. Elkayam,et al.  Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action , 2008, Circulation.

[37]  C. Vassanelli,et al.  Nurse Educational Activity on Non-Prescription Therapies in Patients with Chronic Heart Failure , 2007, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[38]  C. Yancy,et al.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). , 2007, American heart journal.

[39]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[40]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[41]  C. Huerta,et al.  Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population , 2006, Heart.

[42]  R. Falk.  Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.

[43]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[44]  A. Gillinov,et al.  “Renal dose” dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery* , 2005, Critical care medicine.

[45]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[46]  L. Stevenson,et al.  Searching for evidence: Refractory questions in advanced heart failure. , 2004, Journal of cardiac failure.

[47]  N. Marchionni,et al.  Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure* , 2004, Critical care medicine.

[48]  R. Bard,et al.  Food: An Unrecognized Source of Loop Diuretic Resistance , 2004, Pharmacotherapy.

[49]  A. P. Spencer,et al.  Keeping your patient with heart failure safe: a review of potentially dangerous medications. , 2004, Archives of internal medicine.

[50]  A. Hunsche,et al.  Increasing the Dose of Furosemide in Patients With Azotemia and Suspected Obstruction , 2004, Clinical nuclear medicine.

[51]  B. Beermann,et al.  Reduced bioavailability and effect of furosemide given with food , 2004, European Journal of Clinical Pharmacology.

[52]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[53]  D. Sica,et al.  Diuretic use in stage 5 chronic kidney disease and end-stage renal disease , 2003, Current opinion in nephrology and hypertension.

[54]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[55]  L. D. Bruyne.  Mechanisms and management of diuretic resistance in congestive heart failure. , 2003 .

[56]  S. Hernández-Díaz,et al.  Nonsteroidal Antiinflammatory Drugs as a Trigger of Clinical Heart Failure , 2003, Epidemiology.

[57]  D. Sica.  Metolazone and its role in edema management. , 2003, Congestive heart failure.

[58]  C. O'connor,et al.  Diuretic resistance predicts mortality in patients with advanced heart failure. , 2002, American heart journal.

[59]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[60]  C. Wilcox.  New insights into diuretic use in patients with chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[61]  D. Ellison.  Diuretic Therapy and Resistance in Congestive Heart Failure , 2002, Cardiology.

[62]  D. Ellison,et al.  Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. , 2001, Journal of the American Society of Nephrology : JASN.

[63]  R. Bellomo,et al.  Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial , 2000, The Lancet.

[64]  J Pérez-Urizar,et al.  Pharmacokinetic-pharmacodynamic modeling: why? , 2000, Archives of medical research.

[65]  H. Saito,et al.  Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. , 2000, The Journal of pharmacology and experimental therapeutics.

[66]  D. Henry,et al.  Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. , 2000, Archives of internal medicine.

[67]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[68]  J. Nicklas,et al.  Pharmacokinetics of Torsemide in Patients with Decompensated and Compensated Congestive Heart Failure , 1998, Journal of clinical pharmacology.

[69]  M. Fisher,et al.  The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. , 1998, The American journal of medicine.

[70]  W. Barron,et al.  Effect of food on the absorption of frusemide and bumetanide in man. , 2003, British journal of clinical pharmacology.

[71]  V. Pichette,et al.  The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit , 1996, British journal of pharmacology.

[72]  Johan Gabrielsson,et al.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration , 1996, Clinical pharmacology and therapeutics.

[73]  B. Pitt.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[74]  E. Mutschler,et al.  Diuretic Effectiveness of Hydrochlorothiazide and Furosemide Alone and in Combination in Chronic Renal Failure , 1995, Journal of cardiovascular pharmacology.

[75]  D. Brater,et al.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.

[76]  D. Fliser,et al.  Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. , 1994, Kidney international.

[77]  K. Channer,et al.  Combination diuretic treatment in severe heart failure: a randomised controlled trial. , 1994, British heart journal.

[78]  C. Wilcox,et al.  A volume-independent component to postdiuretic sodium retention in humans. , 1993, Journal of the American Society of Nephrology : JASN.

[79]  A. Donker,et al.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. , 1993, The American journal of cardiology.

[80]  D. Brater,et al.  Binding inhibitors restore furosemide potency in tubule fluid containing albumin. , 1991, Kidney International.

[81]  D. Ellison.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance. , 1991, Annals of internal medicine.

[82]  D. Brater,et al.  Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome. , 1990, The Journal of pharmacology and experimental therapeutics.

[83]  R. Unwin,et al.  Mechanism of impaired natriuretic response to furosemide during prolonged therapy. , 1989, Kidney international.

[84]  B. Stanton,et al.  Regulation of renal ion transport and cell growth by sodium. , 1989, The American journal of physiology.

[85]  K. Kirchner.  Role of medullary plasma flow in the attenuated furosemide response in indomethacin-treated rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[86]  B. Stanton,et al.  Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. , 1988, The American journal of physiology.

[87]  B. Stanton,et al.  Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. , 1988, The American journal of physiology.

[88]  J. Nicklas,et al.  Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure , 1988, Clinical pharmacology and therapeutics.

[89]  H. Nakahama,et al.  Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. , 1988, Nephron.

[90]  J. Firth,et al.  RAISED VENOUS PRESSURE: A DIRECT CAUSE OF RENAL SODIUM RETENTION IN OEDEMA? , 1988, The Lancet.

[91]  P. Gerlag,et al.  High-dose furosemide in the treatment of refractory congestive heart failure. , 1988, Archives of internal medicine.

[92]  L. Paalzow,et al.  Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. , 1985, The Journal of pharmacology and experimental therapeutics.

[93]  K. Kirchner.  Prostaglandin inhibitors alter loop segment chloride uptake during furosemide diuresis. , 1985, The American journal of physiology.

[94]  J. V. Nixon,et al.  Furosemide absorption altered in decompensated congestive heart failure. , 1985, Annals of internal medicine.

[95]  G. D. Johnston,et al.  Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. , 1983, Circulation research.

[96]  J. Gerber,et al.  Indomethacin-furosemide interaction: the importance of renal blood flow. , 1983, The Journal of pharmacology and experimental therapeutics.

[97]  D. Wilson,et al.  Furosemide action on collecting ducts: effect of prostaglandin synthesis inhibition. , 1983, The American journal of physiology.

[98]  G. Dehmer,et al.  Absorption and disposition of furosemide in congestive heart failure. , 1982, Kidney international.

[99]  J. Haas,et al.  Segmental analysis of sodium reabsorption during renal vein constriction. , 1982, The American journal of physiology.

[100]  B. Mirkin,et al.  Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. , 1980, Life sciences.

[101]  Miller Ne,et al.  Letter: High-density lipoprotein and atherosclerosis. , 1975, Lancet.

[102]  G. Snodgrass,et al.  Letter: Enamel hypoplasia of the teeth associated with neonatal tetany. , 1973, Lancet.

[103]  J. Forrester,et al.  Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. , 1973, The New England journal of medicine.

[104]  H. E. Williamson,et al.  Effects of several saluretic-diuretic agents on renal hemodynamics. , 1966, The Journal of pharmacology and experimental therapeutics.

[105]  G. Teasdale,et al.  THE DIURETIC RESPONSE TO FRUSEMIDE. , 1964, Lancet.